Bergstra SA, et al. - The goal of this inquiry was to delineate the link between clinical response and methotrexate (MTX) dose as monotherapy or combination therapy in patients with early rheumatoid arthritis (RA). In this patient population, researchers found no clinical benefit of high vs low initial MTX doses for MTX monotherapy or for MTX combination therapy with convention synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs) or glucocorticoids.